Table 3 Statistically significant results of network meta-analysis in randomized controlled trials
Treatment comparison | Number of studies | NMA estimate OR (95% CI)a | MA estimate OR (95% CI) |
|---|---|---|---|
Arrhythmia – 3 RCTs, 4 (inconsistency not applicableb) | |||
No statistically significant results | |||
Mortality – 8 RCTs, 7 treatments, 4823 adults | |||
No statistically significant results | |||
Evaluation of inconsistency using the design-by-treatment interaction model | Chi-squared test: 1.06 | P-value: 0.79 | |
Degrees of freedom: 3 | Heterogeneity: 0.00 | ||
QTc prolongation – 4 RCTs, 7 treatments, 3358 children and adults (inconsistency not applicableb) | |||
Ondansetron + dexamethasone vs dolasetron + dexamethasone | 1 | 0.34 (0.24–0.47) | 0.34 (0.24–0.47) |
Number of patients without nausea – 44 RCTS, 12 treatments plus placebo, 11,664 adults | |||
Ondansetron + steroid vs ondansetron | 8 | 1.96 (1.59–2.41) | 2.16 (1.45–3.23) |
Ondansetron + steroid vs granisetron | 1 | 2.00 (1.63–2.45) | 21.00 (3.35–131.51) |
Ondansetron + steroid vs dolasetron | NA | 2.09 (1.47–2.97) | NA |
Ondansetron + steroid vs dolasetron + steroid | NA | 0.44 (0.20–0.96) | NA |
Ondansetron + steroid vs palonosetron | NA | 1.60 (1.06–2.41) | NA |
Ondansetron + steroid vs tropisetron + steroid | 1 | 2.40 (1.49–3.88) | 7.20 (2.03–25.51) |
Ondansetron + steroid vs placebo | NA | 337.68 (18.89–6035.72) | NA |
Granisetron + steroid vs ondansetron | NA | 1.91 (1.55–2.34) | NA |
Granisetron + steroid vs granisetron | 6 | 1.95 (1.62–2.34) | 1.96 (1.54–2.50) |
Granisetron + steroid vs dolasetron | NA | 2.04 (1.44–2.87) | NA |
Granisetron + steroid vs dolasetron + steroid | NA | 0.43 (0.20–0.93) | NA |
Granisetron + steroid vs palonosetron | NA | 1.55 (1.04–2.33) | NA |
Granisetron + steroid vs tropisetron + steroid | 1 | 2.34 (1.45–3.77) | 7.20 (1.29–40.05) |
Granisetron + steroid vs placebo | NA | 328.52 (18.40–5864.44) | NA |
Ondansetron vs dolasetron + steroid | NA | 0.22 (0.10–0.48) | NA |
Ondansetron vs palonosetron + steroid | NA | 0.53 (0.39–0.73) | NA |
Ondansetron vs tropisetron + steroid | NA | 0.29 (0.13–0.62) | NA |
Ondansetron vs ramosetron + steroid | NA | 0.35 (0.19–0.64) | NA |
Ondansetron vs placebo | NA | 172.34 (9.67–3070.30) | NA |
Granisetron vs dolasetron + steroid | NA | 0.22 (0.10–0.47) | NA |
Granisetron vs palonosetron + steroid | NA | 0.52 (0.39–0.70) | NA |
Granisetron vs tropisetron + steroid | NA | 0.28 (0.13–0.61) | NA |
Granisetron vs ramosetron + steroid | NA | 0.34 (0.19–0.62) | NA |
Granisetron vs placebo | 1 | 168.85 (9.51–2996.71) | 169.00 (9.52–2999.80) |
Dolasetron vs dolasetron + steroid | 1 | 0.21 (0.10–0.42) | 0.21 (0.10–0.42) |
Dolasetron vs palonosetron + steroid | NA | 0.50 (0.33–0.76) | NA |
Dolasetron vs tropisetron + steroid | NA | 0.27 (0.12–0.61) | NA |
Dolasetron vs ramosetron + steroid | NA | 0.33 (0.17–0.63) | NA |
Dolasetron vs placebo | NA | 161.31 (8.95–2907.94) | NA |
Dolasetron + steroid vs palonosetron | NA | 3.65 (1.68–7.94) | NA |
Dolasetron + steroid vs palonosetron + steroid | NA | 2.39 (1.06–5.39) | NA |
Dolasetron + steroid vs tropisetron + steroid | NA | 5.49 (2.27–13.27) | NA |
Dolasetron + steroid vs ramosetron + steroid | NA | 3.19 (1.29–7.85) | NA |
Dolasetron + steroid vs placebo | NA | 771.35 (39.35–15,120.97) | NA |
Palonosetron vs tropisetron + steroid | NA | 0.35 (0.15–0.83) | NA |
Palonosetron vs ramosetron + steroid | NA | 0.43 (0.22–0.86) | NA |
Palonosetron vs placebo | NA | 211.46 (11.64–3841.31) | NA |
Palonosetron + steroid vs tropisetron + steroid | NA | 2.30 (1.35–3.91) | NA |
Palonosetron + steroid vs placebo | NA | 323.08 (17.93–5821.31) | NA |
Tropisetron + steroid vs tropisetron + steroid | 2 | 0.24 (0.13–0.44) | 0.24 (0.13–0.44) |
Tropisetron + steroid vs ramosetron + steroid | NA | 0.29 (0.14–0.60) | NA |
Tropisetron + steroid vs placebo | NA | 140.45 (7.63–2585.40) | NA |
Tropisetron + steroid vs placebo | NA | 597.18 (30.37–11,744.01) | NA |
Ramosetron + steroid vs ramosetron + steroid | 1 | 0.49 (0.31–0.78) | 0.48 (0.29–0.79) |
Ramosetron + steroid vs placebo | NA | 242.02 (13.10–4471.01) | NA |
Ramosetron + steroid vs placebo | NA | 490.92 (26.08–9241.08) | NA |
Evaluation of inconsistency using the design-by-treatment interaction model | Chi-squared test: 15.91 | P-value: 0.1955 | |
Degrees of freedom: 12 | Heterogeneity: 0.00 | ||
Number of patients without vomiting – 63 RCTs, 12 treatments plus placebo, 15,460 adults | |||
Ondansetron + steroid vs ondansetron | 9 | 2.46 (1.80–3.37) | 2.47 (1.52–4.03) |
Ondansetron + steroid vs granisetron | 1 | 2.35 (1.70–3.25) | 21.00 (3.35–131.51) |
Ondansetron + steroid vs dolasetron | NA | 2.83 (1.78–4.51) | NA |
Ondansetron + steroid vs tropisetron | 1 | 2.95 (1.76–4.94) | 7.20 (2.03–25.51) |
Ondansetron + steroid vs placebo | NA | 31.56 (11.42–87.23) | NA |
Granisetron + steroid vs ondansetron | NA | 2.31 (1.66–3.21) | NA |
Granisetron + steroid vs granisetron | 8 | 2.21 (1.64–2.96) | 2.40 (1.21–4.75) |
Granisetron + steroid vs dolasetron | NA | 2.66 (1.66–4.27) | NA |
Granisetron + steroid vs tropisetron | 1 | 2.77 (1.65–4.66) | 34.52 (1.83–650.54) |
Granisetron + steroid vs placebo | NA | 29.64 (10.74–81.82) | NA |
Ondansetron vs dolasetron + steroid | NA | 0.46 (0.24–0.89) | NA |
Ondansetron vs palonosetron | 2 | 0.59 (0.39–0.89) | 0.44 (0.27–0.73) |
Ondansetron vs palonosetron + steroid | NA | 0.33 (0.18–0.59) | NA |
Ondansetron vs tropisetron + steroid | NA | 0.32 (0.12–0.85) | NA |
Ondansetron vs ramosetron + steroid | NA | 0.37 (0.17–0.83) | NA |
Ondansetron vs placebo | 3 | 12.82 (4.85–33.94) | 11.02 (3.30–36.84) |
Granisetron vs dolasetron + steroid | NA | 0.48 (0.25–0.94) | NA |
Granisetron vs palonosetron | 3 | 0.62 (0.42–0.92) | 0.69 (0.48–0.98) |
Granisetron vs palonosetron + steroid | NA | 0.35 (0.20–0.62) | NA |
Granisetron vs tropisetron + steroid | NA | 0.34 (0.13–0.90) | NA |
Granisetron vs ramosetron + steroid | NA | 0.39 (0.18–0.87) | NA |
Granisetron vs placebo | 1 | 13.44 (5.02–35.96) | 78.00 (6.24–974.67) |
Dolasetron vs dolasetron + steroid | 1 | 0.40 (0.20–0.80) | 0.21 (0.09–0.50) |
Dolasetron vs palonosetron | 1 | 0.51 (0.32–0.83) | 0.55 (0.36–0.85) |
Dolasetron vs palonosetron + steroid | NA | 0.29 (0.15–0.57) | NA |
Dolasetron vs tropisetron + steroid | NA | 0.28 (0.10–0.79) | NA |
Dolasetron vs ramosetron + steroid | NA | 0.32 (0.14–0.78) | NA |
Dolasetron vs placebo | NA | 11.14 (3.94–31.49) | NA |
Dolasetron + steroid vs tropisetron | NA | 2.61 (1.20–5.69) | NA |
Dolasetron + steroid vs placebo | NA | 27.92 (8.62–90.43) | NA |
Palonosetron vs tropisetron | NA | 2.02 (1.13–3.63) | NA |
Palonosetron vs placebo | NA | 21.65 (7.60–61.72) | NA |
Palonosetron + steroid vs tropisetron | NA | 3.62 (1.78–7.37) | NA |
Palonosetron + steroid vs ramosetron | NA | 2.24 (1.02–4.91) | NA |
Palonosetron + steroid vs placebo | NA | 38.78 (12.56–119.76) | NA |
Tropisetron vs tropisetron + steroid | 2 | 0.27 (0.11–0.64) | 0.27 (0.13–0.57) |
Tropisetron vs ramosetron + steroid | NA | 0.31 (0.13–0.77) | NA |
Tropisetron vs placebo | NA | 10.70 (3.69–31.01) | NA |
Tropisetron + steroid vs placebo | NA | 39.86 (10.09–157.37) | NA |
Ramosetron vs placebo | 1 | 17.30 (6.20–48.30) | 10.45 (2.21–49.38) |
Ramosetron + steroid vs placebo | NA | 34.31 (10.33–113.92) | NA |
Evaluation of inconsistency using the design-by-treatment interaction model | Chi-squared test: 22.14 | P-value: 0.1387 | |
Degrees of freedom: 16 | Heterogeneity: 0.10 | ||
Number of patients without CINV – 27 RCTs, 10 treatments, 10,924 adults | |||
Ondansetron + steroid vs ondansetron | 1 | 2.16 (1.62–2.87) | 1.96 (1.12–3.42) |
Ondansetron + steroid vs granisetron | NA | 2.17 (1.73–2.72) | NA |
Ondansetron + steroid vs palonosetron + steroid | NA | 0.81 (0.67–0.98) | NA |
Ondansetron + steroid vs tropisetron | NA | 4.18 (1.99–8.77) | NA |
Ondansetron + steroid vs placebo | NA | 365.96 (20.44–6553.02) | NA |
Granisetron + steroid vs ondansetron | NA | 2.23 (1.69–2.93) | NA |
Granisetron + steroid vs granisetron | 6 | 2.24 (1.83–2.74) | 2.35 (1.88–2.94) |
Granisetron + steroid vs palonosetron + steroid | NA | 0.84 (0.70–0.99) | NA |
Granisetron + steroid vs tropisetron | NA | 4.31 (2.07–9.01) | NA |
Granisetron + steroid vs placebo | NA | 378.03 (21.15–6756.45) | NA |
Ondansetron vs palonosetron + steroid | NA | 0.38 (0.27–0.52) | NA |
Ondansetron vs ramosetron + steroid | NA | 0.31 (0.16–0.59) | NA |
Ondansetron vs placebo | NA | 169.61 (9.48–3035.34) | NA |
Granisetron vs palonosetron + steroid | NA | 0.37 (0.29–0.49) | NA |
Granisetron vs ramosetron + steroid | NA | 0.31 (0.16–0.60) | NA |
Granisetron vs placebo | 1 | 168.85 (9.51–2996.64) | 169.00 (9.52–2999.80) |
Palonosetron vs placebo | NA | 165.47 (6.55–4182.08) | NA |
Palonosetron + steroid vs tropisetron | NA | 5.16 (2.43–10.97) | NA |
Palonosetron + steroid vs placebo | NA | 452.19 (25.18–8121.41) | NA |
Tropisetron vs ramosetron | NA | 0.35 (0.14–0.83) | NA |
Tropisetron vs ramosetron + steroid | NA | 0.16 (0.06–0.42) | NA |
Tropisetron vs placebo | NA | 87.64 (4.53–1696.76) | NA |
Ramosetron vs ramosetron + steroid | 1 | 0.46 (0.29–0.73) | 0.55 (0.34–0.89) |
Ramosetron vs placebo | NA | 253.30 (13.55–4734.53) | NA |
Ramosetron + steroid vs placebo | NA | 546.71 (28.58–10,456.90) | NA |
Evaluation of inconsistency using the design-by-treatment interaction model | Chi-squared test: 11.95 | P-value: 0.0631 | |
Degrees of freedom: 6 | Heterogeneity: 0.00 | ||
Number of patients experiencing severe vomiting – 10 RCTs, 5 treatments, 917 adults | |||
Ondansetron vs granisetron | 4 | 0.65 (0.45–0.94) | 0.63 (0.43–0.93) |
Ondansetron vs placebo | 3 | 0.16 (0.04–0.70) | 0.16 (0.04–0.70) |
Ramosetron vs placebo | NA | 0.18 (0.03–0.95) | NA |
Evaluation of inconsistency using the design-by-treatment interaction model | Chi-squared test: 0.33 | P-value: 0.5628 | |
Degrees of freedom: 1 | Heterogeneity: 0.00 | ||